NO20016121L - Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 - Google Patents
Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1Info
- Publication number
- NO20016121L NO20016121L NO20016121A NO20016121A NO20016121L NO 20016121 L NO20016121 L NO 20016121L NO 20016121 A NO20016121 A NO 20016121A NO 20016121 A NO20016121 A NO 20016121A NO 20016121 L NO20016121 L NO 20016121L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- abc
- relates
- polypeptides
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Addiction (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
Foreliggende oppfinnelse angår nye ABC 1-polypeptider og nukleinsyremolekyler som koder for det samme. Oppfinnelsen angår også rekombinante vektorer, vertsceller og preparater som omfatter ABCl-polynukleotider, så vel som fremgangsmåter for å frem-stille ABC 1-polypeptider. Oppfinnelsen angår også antistoffer som binder spesifikt til ABC 1-polypeptider. I tillegg angår oppfinnelsen fremgangsmåter for å øke kolesterolut-strømning så vel som fremgangsmåter for å øke ABC 1-ekspresjon og aktivitet. Foreliggende oppfinnelse angår videre fremgangsmåter for å identifisere forbindelser som modulerer ekspresjonen av ABC1 samt fremgangsmåter for å påvise det komparative nivå-et av ABC 1-polypeptider og polynukleotider i et pattedyr. Foreliggende oppfinnelse tilveiebringer også kit og preparater som er egnet til å screene forbindelser for å bestemme den ABCl-ekspresjonsmodulerende aktiviteten til forbindelsen, så vel som kit og preparater som er egnet til å bestemme hvorvidt en forbindelse modulerer ABC1-avhengig kolesterolutstrømning.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 | |
| PCT/US2000/016591 WO2000078971A2 (en) | 1999-06-18 | 2000-06-16 | Atp binding cassette transporter protein abc1 popypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20016121D0 NO20016121D0 (no) | 2001-12-14 |
| NO20016121L true NO20016121L (no) | 2002-02-12 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016121A NO20016121L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
| NO20016114A NO20016114L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016114A NO20016114L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1218515B1 (no) |
| JP (4) | JP2003508031A (no) |
| KR (2) | KR100476519B1 (no) |
| CN (2) | CN1379817A (no) |
| AR (2) | AR024576A1 (no) |
| AT (1) | ATE422545T1 (no) |
| AU (3) | AU5743400A (no) |
| BR (2) | BR0011696A (no) |
| CA (2) | CA2375787C (no) |
| DE (1) | DE60041545D1 (no) |
| HK (2) | HK1046427A1 (no) |
| IL (2) | IL147021A0 (no) |
| MX (2) | MXPA01013174A (no) |
| NO (2) | NO20016121L (no) |
| NZ (3) | NZ529785A (no) |
| SG (2) | SG121852A1 (no) |
| TR (2) | TR200200441T2 (no) |
| TW (2) | TWI259205B (no) |
| WO (2) | WO2000078972A2 (no) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| DE60035163T2 (de) | 1999-03-15 | 2008-02-21 | University Of British Columbia, Vancouver | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts |
| WO2001003705A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| AU1291901A (en) * | 1999-09-01 | 2001-03-26 | University Of British Columbia, The | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| US7378274B2 (en) | 2000-05-02 | 2008-05-27 | Aventis Pharma S.A. | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
| WO2003033023A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Drugs ameliorating hypo-hdl cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465882B1 (en) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Hetrocyclic modulators of nuclear receptors |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| ES2361924T3 (es) | 2002-12-20 | 2011-06-24 | X-Ceptor Therapeutics, Inc. | Derivados de isoquinolinona y su uso como agentes terapéuticos. |
| BRPI0412262A (pt) | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| MX2008000141A (es) | 2005-06-27 | 2008-04-07 | Exelixis Inc | Moduladores de lxr basados en imidazol. |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| EP2115004A2 (en) | 2006-12-19 | 2009-11-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| WO2010120508A2 (en) * | 2009-03-31 | 2010-10-21 | The General Hospital Corporation | Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders |
| EP2417163B1 (en) | 2009-04-10 | 2019-02-27 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| DK2435410T3 (da) | 2009-05-28 | 2017-04-10 | Exelixis Patent Co Llc | LXR-modulatorer |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| KR101650995B1 (ko) | 2010-11-08 | 2016-08-25 | 노파르티스 아게 | Ｃｘｃｒ２ 결합 폴리펩티드 |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| ES2694001T3 (es) | 2013-03-15 | 2018-12-17 | Bristol-Myers Squibb Company | Moduladores de LXR |
| WO2014144037A1 (en) | 2013-03-15 | 2014-09-18 | Bristol-Myers Squibb Company | Lxr modulators |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| CA3006398A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| EP3512880A1 (en) | 2016-09-15 | 2019-07-24 | Ablynx NV | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| AU2017361846B2 (en) | 2016-11-16 | 2024-08-22 | Ablynx Nv | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| IL270951B2 (en) | 2017-06-02 | 2025-05-01 | Merck Patent Gmbh | ADAMTS5, MMP13 and aggrecan-binding polypeptides |
| KR102778120B1 (ko) | 2017-06-02 | 2025-03-06 | 메르크 파텐트 게엠베하 | Mmp13 결합성 면역글로불린 |
| CN110997716B (zh) | 2017-06-02 | 2024-03-15 | 埃博灵克斯股份有限公司 | 结合聚集蛋白聚糖的免疫球蛋白 |
| LT3630847T (lt) | 2017-06-02 | 2024-12-10 | Merck Patent Gmbh | Adamts surišantys imunoglobulinai |
| CN115551526A (zh) * | 2020-03-06 | 2022-12-30 | 安度利体技术公司 | 用于治疗细胞内细菌感染的组合物和方法 |
| WO2022253340A1 (zh) | 2021-06-04 | 2022-12-08 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| JP2025523049A (ja) | 2022-07-14 | 2025-07-17 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 抗Ｎｅｃｔｉｎ－４抗体及びその使用 |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133774A1 (es) | 2023-09-11 | 2025-10-29 | Novo Nordisk As | Anticuerpos de dominio anti-il-6 |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025207946A1 (en) | 2024-03-28 | 2025-10-02 | Genzyme Corporation | Polypeptides binding to a specific epitope of the transferrin receptor 1 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378274B2 (en) * | 2000-05-02 | 2008-05-27 | Aventis Pharma S.A. | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
-
2000
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Ceased
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Ceased
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active Expired - Fee Related
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/zh unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Ceased
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
-
2001
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20016121L (no) | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 | |
| Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
| DK1012274T3 (da) | Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L) | |
| ATE352618T1 (de) | Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält | |
| DK1032660T3 (da) | Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop | |
| DK0981618T4 (da) | Anti-Apo-2-antistof | |
| NO20060236L (no) | Antistoffer spesifikke for sklerostinro og fremgangsmate for a oke benmineralisering | |
| CA2063822A1 (en) | Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators | |
| AU1155395A (en) | Retinoid receptor compositions, antibodies and methods | |
| CA2148252A1 (en) | Interaction trap system for isolating novel proteins | |
| DK0576623T4 (da) | Bindingsdomæner i Notch-proteiner | |
| DK1005488T4 (da) | Receptor som binder TRAIL | |
| EP1454992B1 (en) | Anaplastic lymphoma kinase assay, reagents and compositions thereof | |
| WO1999043808A8 (en) | Human c-maf compositions and methods of use thereof | |
| WO2005069900B1 (en) | Npc1l1 (npc3) and methods of identifying ligands thereof | |
| Hochrein et al. | An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry | |
| WO1999047686A3 (en) | Human mekk proteins, corresponding nucleic acid molecules, and uses therefor | |
| ATE308615T1 (de) | T-bet zusammensetzungen und deren vervendungsmethoden | |
| WO2002087606A3 (en) | Modulators of the hypocretin system and methods of screening therefor | |
| NO983984L (no) | Disintegrin-metalloprotease samt anvendelse derav | |
| EA200300420A1 (ru) | Выделенная молекула нуклеиновой кислоты, выделенный полипептид и способ его получения, способ обнаружения их присутствия в образце (варианты), клетка-хозяин (варианты), антитело, набор (варианты), способ модулирования активности полипептида, способ идентификации (варианты) и применение соединения, способ выявления субъекта (варианты) и способ лечения субъекта с нарушением, связанным с калиевыми каналами (варианты) | |
| Zitterbart et al. | Immobilization methods for the rapid total chemical synthesis of proteins on microtiter plates | |
| WO2001066745A3 (en) | Presenilin/crk binding polypeptides (pcbp) and methods of use thereof | |
| WO2001061001A3 (de) | Neues zentralnervöses protein, das k+-ströme moduliert | |
| WO2000007545A3 (en) | Apoptosis proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |